

ASX Announcement

Imugene PD1-Vaxx Update

Sydney, Australia, 12 September 2023: Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to provide an update on development of its PD1-Vaxx clinical drug candidate.

Imugene announces the grant of a new patent (number 2019-553504) by the Japanese Patent Office. The granted claims protect Imugene's immunotherapeutic PD1-Vaxx, a first-in-class programmed death-1 (PD1) vaccine, currently in clinical development for non-small cell lung cancer (NSCLC).

The patent titled "HUMAN PD1 PEPTIDE VACCINES AND USES THEREOF" will expire on 28 March 2038 and protects the composition of matter and method of treatment in cancer of Imugene's PD1-Vaxx for the generation of a therapeutic antibody response against the PD1 checkpoint target.

Imugene's PD1-Vaxx is a B-cell activating immunotherapy designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction and produce an anti-cancer effect similar to Keytruda®, Opdivo® and the other immune checkpoint inhibitor monoclonal antibodies that are transforming the treatment of a range of cancers.

Last week marked 1000 days cancer free for a patient with late-stage NSCLC who was recruited and dosed in December 2020. This week Professor Michael Boyer M.D., MBBS, FRACP, PhD, Chris O'Brien Lifehouse Hospital will present a trial-in-progress poster in person at the IASLC 2023 World Conference on Lung Cancer (WCLC 2023) in Singapore. The poster presentation can be downloaded from Imugene's website, <https://www.imugene.com/conference-presentations>

Imugene MD & CEO Leslie Chong said: "Attaining the key Japanese patent, on top of gaining protection in the USA this year, is a very important milestone. Recruitment in the Phase 1



PD1-Vaxx trial, as monotherapy or in combination with atezolizumab in adults with Non-Small Cell Lung Cancer, has increased markedly recently with strong interest from new clinical sites to participate in this innovative study”.

For more information please contact:

Leslie Chong
Managing Director and Chief Executive Officer
info@imugene.com

Investor Enquiries
shareholderenquiries@imugene.com

Media Enquiries
Matt Wright
matt@nwrcommunications.com.au

Follow us on Twitter and Instagram @TeamImugene
Like us on Facebook @Imugene
Connect with us on LinkedIn @Imugene Limited
Watch us on YouTube @ImugeneLimited

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumours. Our unique platform technologies seek to harness the body's immune system against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody and other immunotherapies. Our product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug azer-cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer, multiple immunotherapy B-cell vaccine candidates and an oncolytic virotherapy (CF33) aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies such as CAR T's for solid tumours. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer



therapies with many approved for sale and marketing for global markets. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peer-reviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene's immuno-oncology therapies will become foundation treatments for cancer. Our goal is to ensure that Imugene and its shareholders are at the forefront of this rapidly growing global market.

Release authorised by the Managing Director and Chief Executive Officer Imugene Limited.